Trial Profile
A Phase 3 Multinational, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Ph+ CML Patients in Early Chronic Phase
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Radotinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms RERISE
- Sponsors Il-Yang Pharmaceutical
- 04 Dec 2018 Results asssessing efficacy of radotinib vs imatinib in chronic myeloid leukemia patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 22 Sep 2017 Primary endpoint has been met. (Rate of Major Molecular Response(MMR) by 12 months) as per result published in the Clinical cancer research: an official journal of the American Association for Cancer Research